GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (OTCPK:SPHRY) » Definitions » Price-to-Owner-Earnings

Starpharma Holdings (Starpharma Holdings) Price-to-Owner-Earnings : (As of May. 19, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Starpharma Holdings Price-to-Owner-Earnings?

As of today (2024-05-19), Starpharma Holdings's share price is $0.7225. Starpharma Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Starpharma Holdings's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Starpharma Holdings was 66.67. The lowest was 30.42. And the median was 52.92.


SPHRY's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.58
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-19), Starpharma Holdings's share price is $0.7225. Starpharma Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.15. Therefore, Starpharma Holdings's PE Ratio for today is At Loss.

As of today (2024-05-19), Starpharma Holdings's share price is $0.7225. Starpharma Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.15. Therefore, Starpharma Holdings's PE Ratio without NRI for today is At Loss.


Starpharma Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for Starpharma Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings Price-to-Owner-Earnings Chart

Starpharma Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Starpharma Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Starpharma Holdings's Price-to-Owner-Earnings

For the Biotechnology subindustry, Starpharma Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Starpharma Holdings's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's Price-to-Owner-Earnings falls into.



Starpharma Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Starpharma Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.7225/-0.24
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Starpharma Holdings  (OTCPK:SPHRY) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Starpharma Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Starpharma Holdings (Starpharma Holdings) Business Description

Traded in Other Exchanges
Address
4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.